Charles River Laboratories International, Inc. · NYSE:CRL

Charles River Laboratories International — Q2 2026 Earnings Presentation

11 slides from Charles River Laboratories International's earnings presentation, 2026

1. Slide 1: 2Q26 Regulation G Financial Reconciliations & Appendix

   2Q26 Regulation G Financial Reconciliations & Appendix © 2026 Charles River Laboratories International, Inc.

2. Slide 2: Reconciliation of GAAP to Non-GAAP: Selected Business Segment Information

   CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF GAAP TO NON-GAAP SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)(1) (in thousands, except percentages) Three Months Ended Six Months Ended June 27, 2026 June 28, 2025 June 27, 2026 June 28, 2025 Research Models and Services Revenue $

3. Slide 3: Reconciliation of GAAP to Non-GAAP: Segment Information (Continued)

   CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF GAAP TO NON-GAAP SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)(1) (in thousands, except percentages) Three Months Ended Six Months Ended June 27, 2026 June 28, 2025 June 27, 2026 June 28, 2025 CONTINUED FROM PREVIOUS SLIDE Unalloca

4. Slide 4: Reconciliation of GAAP Earnings (Loss) to Non-GAAP Earnings

   CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF GAAP EARNINGS (LOSS) TO NON-GAAP EARNINGS (UNAUDITED) (1) (in thousands, except per share data) Three Months Ended Six Months Ended June 27, 2026 June 28, 2025 June 27, 2026 June 28, 2025 Net income (loss) available to Charles River La

5. Slide 5: Reconciliation of GAAP Revenue Growth to Non-GAAP Organic Revenue Growth

   CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF GAAP REVENUE GROWTH TO NON-GAAP REVENUE GROWTH, ORGANIC (UNAUDITED) (1) Three Months Ended June 27, 2026 Total CRL RMS Segment DSA Segment MS Segment Revenue growth, reported (2.7)% (1.8)% (1.9)% (6.3)% (Increase) decrease due to forei

6. Slide 6: Reconciliation of GAAP to Non-GAAP Revenue and EPS Guidance

   CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF GAAP TO NON-GAAP REVENUE AND EARNINGS PER SHARE (EPS) Guidance for the Twelve Months Ended December 26, 2026E 2026 GUIDANCE (1) CURRENT PRIOR Revenue growth/(decrease), reported (3.5)% - (2.5)% (5.5)% - (4.0)% Less: Contribution from a

7. Slide 7: Reconciliation of GAAP Tax Rate to Non-GAAP Tax Rate

   CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF GAAP TAX RATE TO NON-GAAP TAX RATE (UNAUDITED) (1) (in thousands) Three Months Ended Six Months Ended June 27, 2026 March 28, 2026 June 28, 2025 June 27, 2026 June 28, 2025 Income (loss) before income taxes & noncontrolling interests $

8. Slide 8: Reconciliation of GAAP to Non-GAAP Interest Expense

   CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF GAAP TO NON-GAAP INTEREST EXPENSE (UNADUTED) (1) (in thousands) Three Months Ended Six Months Ended June 27, 2026 June 28, 2025 June 27, 2026 June 28, 2025 Interest expense, net $ (29,308) $ (28,870) $ (55,017) $ (55,350) Exclude: Accr

9. Slide 9: Reconciliation of Gross/Net Leverage Ratio to Adjusted EBITDA

   CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF GROSS/NET LEVERAGE RATIO, INCLUDING GAAP NET INCOME TO ADJUSTED EBITDA (UNAUDITED) (1) (dollars in thousands, except for per share data) June 27, 2026 March 28, 2026 December 27, 2025 December 28, 2024 December 30, 2023 December 31, 20

10. Slide 10: Reconciliation of Free Cash Flow (Non-GAAP)

    CHARLES RIVER LABORATORIES INTERNATIONAL, INC. RECONCILIATION OF FREE CASH FLOW (NON-GAAP) (UNAUDITED) (1) (in thousands) Three Months Ended Six Months Ended 2026 Guidance June 27, 2026 June 28, 2025 June 27, 2026 June 28, 2025 FYE December 26, 2026E Net cash provided by operating activities $ 179,7

11. Slide 11: © 2026 Charles River Laboratories International, Inc.

    © 2026 Charles River Laboratories International, Inc.

Charles River Laboratories International — Q2 2026 Earnings Presentation on 6ix